Ocular Toxoplasmosis
No Results
No Results
processing….
The most common finding in congenital toxoplasmosis is the ophthalmologic manifestation retinochoroiditis, which has a predilection for the posterior pole. It is seen in 75-80% of cases and is bilateral in 85% of cases. [1, 2] In acquired toxoplasmosis, the ocular form of the disease occurs much less frequently. Previously, only 1-3% of patients with acquired infection were believed to develop ocular toxoplasmosis. However, serologic studies suggest that ocular toxoplasmosis is more commonly associated with acquired infection than was previously believed. (See the images below.)
Consultations with internal medicine or infectious disease specialists are always recommended in the treatment of ocular toxoplasmosis.
Early studies proposed that most cases of ocular toxoplasmosis were secondary to congenital infection and that they tended to occur during the chronic phase of infection. Because reports showed that up to 75% of patients with congenital toxoplasmosis had chorioretinal scars at birth, most cases of intraocular toxoplasmosis were believed to be secondary to reactivation of a congenital infection. In contrast, ocular lesions in patients who acquired toxoplasmosis after birth were not found to be common.
However, later studies demonstrated the importance of acquired infection in the pathogenesis of ocular toxoplasmosis. Brazilian studies showed that only 1% of young children with toxoplasmosis had ocular lesions, whereas 21% of persons older than 13 years had ocular lesions. [3] Moreover, in a Canadian epidemic of toxoplasmosis, up to 21% of persons who were affected developed ocular lesions. [4] Serologic studies suggest that ocular toxoplasmosis is more commonly associated with acquired infection than previously believed. [5, 6, 7, 8] Typically, toxoplasmosis has been associated with the ingestion of undercooked meat contaminated with tissue cysts of Toxoplasma gondii. [9] More recently, it has been recognized that water contaminated with oocysts are an important source of infection. [10]
Only 1-2% of patients with the human immunodeficiency virus (HIV) are affected with ocular toxoplasmosis. [11, 12] Elderly patients who acquire toxoplasmosis are at a risk of developing a severe retinochoroiditis, presumably secondary to the waning of cellular immune function that occurs with aging. Local immunosuppression has been associated with intraocular toxoplasmosis. [13, 14]
The hallmark of ocular toxoplasmosis is a necrotizing retinochoroiditis, which may be primary or recurrent. In primary ocular toxoplasmosis, a unilateral focus of necrotizing retinitis is present at the posterior pole in more than 50% of cases. The area of necrosis usually involves the inner layers of the retina and is described as a whitish, fluffy lesion surrounded by retinal edema. The retina is the primary site for the multiplying parasites, while the choroid and the sclera may be the sites of contiguous inflammation. [15, 16, 17]
When the disease involves the optic nerve, the typical manifestation is optic neuritis or papillitis (shown in the image below) associated with edema, often called Jensen disease.
The sheath of the optic nerve may serve as a conduit for the direct spread of Toxoplasma organisms into the optic nerve from an adjacent cerebral infection. This also results in optic neuritis or papillitis.
Punctate outer toxoplasmosis has been described in Japanese and American literature. This form of the disease is unique in that the classic large, atrophic, posterior lesions are not seen.
Inflammatory cells are seen in the vitreous overlying the retinochoroidal or papillary lesion. In many cases, the inflammatory reaction is severe, and the details of the fundus are not visible. This appearance has been termed a “headlight in the fog.” Posterior vitreous detachment is commonly seen, and patients may develop precipitates of inflammatory cells on the posterior vitreous face, referred to as vitreous precipitates. Thick, vitreous strands and membranes may be present and may require vitrectomy.
Toxoplasma antigens are responsible for a hypersensitivity reaction that may result in retinal vasculitis and granulomatous or nongranulomatous anterior uveitis.
Posterior synechiae may complicate the course of anterior uveitis, and keratic precipitates (KP) may be seen. The KP may appear in the classic Arlt distribution in milder, nongranulomatous configurations and granulomatous morphology. In addition, some patients present with the stellate KP pattern, characterized by a diffuse, homogeneous distribution pattern and a stellate, fibrillar KP morphology.
As the lesion heals, it appears as a punched-out scar, revealing white, underlying sclera. This results from extensive retinal and choroidal necrosis surrounded by variable pigment proliferation.
With reactivation of live tissue cysts located at the border of the scars (recurrent ocular toxoplasmosis), the areas of newly active necrotizing retinitis are usually adjacent to old scars (so-called satellite lesions). In some patients, multiple grayish white dots at the level of the retinal pigment epithelium (RPE) appear. No associated vitreous reaction occurs with this manifestation.
As in other inflammatory conditions, macular edema may be seen. Rarely, ocular inflammation without the necrotizing retinochoroiditis can occur in patients with acquired toxoplasmosis. These patients present with retinal vasculitis, vitreitis, and anterior uveitis. Later, they may develop retinochoroidal scars that suggest that the inflammatory reaction was secondary to Toxoplasma gondii.
Rarely, retinal and optic nerve neovascularization may follow. [18, 19] The neovascularization usually regresses with resolution of the inflammation. The exact etiology of neovascularization of the optic nerve and the retina is not well understood. Retinal ischemia associated with severe retinal vasculitis may predispose to neovascularization of the retina. On the other hand, inflammatory reactions alone may cause neovascularization of the retina.
Elevated intraocular pressure at initial examination reflects the severity of inflammation in ocular toxoplasmosis. [20]
Associated serous retinal detachments appear to be more common than previously believed. They usually resolve after 6 weeks. [21]
Fluorescein angiography (FA) of active lesions shows hypofluorescence during the early phase of the study, followed by progressive hyperfluorescence secondary to leakage.
Indocyanine green (ICG) of active lesions is mostly hypofluorescent. ICG has imaged hypofluorescent satellite lesions that are not imaged by FA and are not seen during clinical examination. The etiology of such hypofluorescent lesions is unknown but is suspected of being a noninfectious, perilesional inflammatory reaction. Acute choroidal ischemia may be seen in conjunction with serous retinal detachment. [21]
Optical coherence tomography (OCT) scanning is helpful in identifying potential complications, including epiretinal membrane, cystoid macular edema, vitreoretinal traction, choroidal neovascularization, and serous retinal detachments. [21] Active toxoplasmic lesions have been imaged with OCT and have been characterized by a highly reflective intraretinal area corresponding with the area of retinitis that also shadows the underlying choroid. The posterior hyaloid is thickened and detached over the lesion. [22]
Ultrasonography is indicated in the presence of ocular media opacities, especially vitreous opacities. The most common findings include intravitreal punctiform echoes, thickening of the posterior hyaloid, partial or total posterior vitreous detachment, and focal retinochoroidal thickening.
Atypical cases may require either a vitreous sample or an aqueous sample. Antitoxoplasma immunoglobulin G (IgG) or IgA antibodies may be detected in either an aqueous sample or a vitreous sample. A coefficient is calculated by comparing the concentration of anti-Toxoplasma antibody in the eye and the serum, divided by the concentration of gamma globulin in the aqueous to that in the serum. A coefficient of 8 or higher is consistent with active ocular toxoplasmosis.
Histopathology is the criterion standard for diagnosis. Tissue diagnosis is impractical and rarely used clinically. A retinal biopsy infrequently may be required to elucidate the diagnosis in a highly atypical case. In histologic sections, the tachyzoites appear ovoid or crescent shaped. They measure 6-7 µm in length and 2-3 µm in width.
The tachyzoites stain well with Giemsa stain and Wright stain. Giemsa-stained smears reveal a bluish cytoplasm and a reddish spherical or ovoid nucleus. In the cyst forms, the wall is eosinophilic, argyrophilic, and weakly periodic acid-Schiff (PAS) positive. The cyst may contain anywhere from 50-3000 bradyzoites. The bradyzoites within the cyst are strongly PAS positive. They form intracellularly within vacuoles. The surrounding membrane is produced by the parasite.
An intense inflammatory reaction is present in the retina, the overlying vitreous, and the underlying choroid. The choroid adjacent to the retinal foci usually shows a granulomatous inflammation. The retina is partially necrotic, with a well-defined border between necrotic and unaffected retina. After healing, the retina in the area of infection is destroyed, and chorioretinal adhesions are present.
A zone 1 area is defined where there is a high risk of sustaining permanent visual loss. This area is defined as 2 disk diameters from the fovea (which happens to be an area enclosed by the major temporal arcades) or 1500 µm from the margins of the optic disc. If toxoplasmic retinochoroiditis occurs within zone 1, aggressive treatment should be instituted immediately.
In the case of ocular toxoplasmosis, several therapeutic regimens have been recommended. Triple drug therapy refers to pyrimethamine (loading dose of 75-100 mg during the first day, followed by 25-50 mg on subsequent days), sulfadiazine (loading dose of 2-4 g during the first 24 h followed by 1 g qid), and prednisone. Quadruple therapy refers to pyrimethamine, sulfadiazine, clindamycin, and prednisone (1 mg/kg of weight). Pyrimethamine should be combined with folinic acid to avoid hematologic complications. The duration of treatment varies depending on the patient’s response but usually lasts for 4-6 weeks.
A combination of 60 mg of trimethoprim and 160 mg of sulfamethoxazole given every 3 days was used as prophylaxis against recurrence of toxoplasmic retinochoroiditis. After a follow-up of 20 months, the recurrences were seen in only 6.6% of patients taking the combination, in comparison with 23.6% of patients taking the placebo. [23]
During pregnancy, spiramycin and sulfadiazine can be used in the first trimester. Throughout the second trimester, spiramycin, sulfadiazine, pyrimethamine, and folinic acid are recommended. Spiramycin, pyrimethamine, and folinic acid may be used during the third trimester. [24]
Topical corticosteroids are used depending on the anterior chamber reaction. Depot steroid therapy is absolutely contraindicated in the treatment of ocular toxoplasmosis. The high-dose medication in close proximity to ocular tissues apparently overwhelms the host’s immune response, leading to rampant necrosis and the potential for a blind, phthisical globe. Systemic corticosteroids are used as an adjunct to minimize collateral damage from the inflammatory response.
Topical cycloplegic agents are used depending on the anterior chamber reaction and the degree of pain. They are also used to prevent formation of posterior synechiae.
Antitoxoplasmic agents include the following:
Sulfadiazine
Clindamycin – Intravitreal clindamycin (0.1 mg/0.1 mL) was reported to be beneficial as salvage therapy in eyes that did not respond to conventional oral treatment [25]
Pyrimethamine
Atovaquone – 750 mg qid; has been used as second-line therapy for toxoplasmosis
Azithromycin – 250 mg/d or 500 mg every other day in combination with pyrimethamine 100 mg on the first day followed by 50 mg/d on subsequent days; has also been used as an alternative
A randomized clinical trial demonstrated a comparable effect of intravitreal clindamycin (1 mg) plus intravitreal dexamethasone (400 µg) with the triple therapy of sulfadiazine (loading dose of 4 g daily for 2 d followed by 500 mg qid), pyrimethamine (loading dose of 75 mg for 2 d followed by 25 mg daily), folinic acid (5 mg qd), and prednisolone (1 mg/kg starting on the third day of therapy) for 6 weeks in the treatment of toxoplasmic retinochoroiditis. [26]
In the study, the reduction in lesion size, reduction in vitreous inflammation, and improvement in visual acuity was similar in both groups. Intravitreal clindamycin plus dexamethasone may be an acceptable and effective alternative in selected patients with toxoplasmic retinochoroiditis and may offer patients greater convenience, a safer systemic side-effect profile, greater availability, and fewer follow-up visits and hematologic evaluations.
A combination of trimethoprim (60 mg) and sulfamethoxazole (160 mg) was shown to cause a 59% reduction in lesion size, as compared with a 61% reduction in eyes treated with sulfadiazine and pyrimethamine. [27]
In select cases, intravitreal therapy with clindamycin (1 mg) and dexamethasone (400 µg) may be indicated. [26] Another alternative involves an intravitreal injection of trimethoprim and sulfamethoxazole combined with intravitreal dexamethasone. [28]
Caution must be exercised if photocoagulation or cryotherapy is being considered in the treatment of intraocular toxoplasmosis. Intraretinal hemorrhages, vitreous hemorrhage, and retinal detachment have been reported as complications of such treatment. Tissue cysts can exist in a normal-appearing retina.
Pars plana vitrectomy may be indicated in cases of retinal detachment secondary to vitreous traction or in cases where vitreous opacities persist. Vitreoretinal consultation is desired if pars plana vitrectomy is being considered.
Couvreur J, Desmonts G. Congenital and maternal toxoplasmosis. A review of 300 congenital cases. Dev Med Child Neurol. 1962 Oct. 4:519-30. [Medline].
Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics. 1980 Nov. 66(5):767-74. [Medline].
Glasner PD, Silveira C, Kruszon-Moran D, et al. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol. 1992 Aug 15. 114(2):136-44. [Medline].
Bowie WR, King AS, Werker DH, et al. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet. 1997 Jul 19. 350(9072):173-7. [Medline].
de-la-Torre A, Lopez-Castillo CA, Gomez-Marin JE. Incidence and clinical characteristics in a Colombian cohort of ocular toxoplasmosis. Eye (Lond). 2009 May. 23(5):1090-3. [Medline].
Silveira C, Belfort R Jr, Burnier M Jr, Nussenblatt R. Acquired toxoplasmic infection as the cause of toxoplasmic retinochoroiditis in families. Am J Ophthalmol. 1988 Sep 15. 106(3):362-4. [Medline].
Phan L, Kasza K, Jalbrzikowski J, et al. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol. 2008 Sep. 146(3):375-384. [Medline]. [Full Text].
Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol. 2004 Jan. 137(1):1-17. [Medline].
Jones JL, Dubey JP. Foodborne toxoplasmosis. Clin Infect Dis. 2012 Sep. 55(6):845-51. [Medline].
Jones JL, Dubey JP. Waterborne toxoplasmosis–recent developments. Exp Parasitol. 2010 Jan. 124(1):10-25. [Medline].
Jabs DA, Green WR, Fox R, Polk BF, Bartlett JG. Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology. 1989 Jul. 96(7):1092-9. [Medline].
Elkins BS, Holland GN, Opremcak EM, et al. Ocular toxoplasmosis misdiagnosed as cytomegalovirus retinopathy in immunocompromised patients. Ophthalmology. 1994 Mar. 101(3):499-507. [Medline].
Olson DJ, Parhiz AT, Wirthlin RS. Reactivation of Latent Toxoplasmosis Following Dexamethasone Implant Injection. Ophthalmic Surg Lasers Imaging Retina. 2016 Nov 1. 47 (11):1050-1052. [Medline].
Nijhawan R, Bansal R, Gupta N, Beke N, Kulkarni P, Gupta A. Intraocular cysts of toxoplasma gondii in patients with necrotizing retinitis following periocular/intraocular triamcinolone injection. Ocul Immunol Inflamm. 2013 Oct. 21 (5):396-9. [Medline].
Cordeiro CA, Moreira PR, Costa GC, et al. Interleukin-1 gene polymorphisms and toxoplasmic retinochoroiditis. Mol Vis. 2008. 14:1845-9. [Medline]. [Full Text].
Cordeiro CA, Moreira PR, Andrade MS, et al. Interleukin-10 gene polymorphism (-1082G/A) is associated with toxoplasmic retinochoroiditis. Invest Ophthalmol Vis Sci. 2008 May. 49(5):1979-82. [Medline].
Cordeiro CA, Moreira PR, Costa GC, et al. TNF-alpha gene polymorphism (-308G/A) and toxoplasmic retinochoroiditis. Br J Ophthalmol. 2008 Jul. 92(7):986-8. [Medline].
Benevento JD, Jager RD, Noble AG, et al. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol. 2008 Aug. 126(8):1152-6. [Medline]. [Full Text].
Ben Yahia S, Herbort CP, Jenzeri S, et al. Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. Int Ophthalmol. 2008 Aug. 28(4):311-6. [Medline].
Dodds EM, Holland GN, Stanford MR, et al. Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. Am J Ophthalmol. 2008 Dec. 146(6):856-65.e2. [Medline].
Khairallah M, Kahloun R, Ben Yahia S, Jelliti B. Clinical, tomographic, and angiographic findings in patients with acute toxoplasmic retinochoroiditis and associated serous retinal detachment. Ocul Immunol Inflamm. 2011 Oct. 19 (5):307-10. [Medline].
Monnet D, Averous K, Delair E, Brezin AP. Optical coherence tomography in ocular toxoplasmosis. Int J Med Sci. 2009. 6(3):137-8. [Medline]. [Full Text].
Silveira C, Belfort R Jr, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002 Jul. 134(1):41-6. [Medline].
Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics. 2004 Jun. 113(6):1567-72. [Medline].
Sobrin L, Kump LI, Foster CS. Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina. 2007 Sep. 27(7):952-7. [Medline].
Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011 Jan. 118(1):134-41. [Medline].
Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005 Nov. 112(11):1876-82. [Medline].
Souza CE, Nascimento H, Lima A, Muccioli C, Belfort R Jr. Intravitreal Injection of Sulfamethoxazole and Trimethoprim Associated with Dexamethasone as an Alternative Therapy for Ocular Toxoplasmosis. Ocul Immunol Inflamm. 2017 Apr 27. 1-4. [Medline].
Lihteh Wu, MD Ophthalmologist, Costa Rica Vitreo and Retina Macular Associates
Lihteh Wu, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, Club Jules Gonin, Macula Society, Pan-American Association of Ophthalmology, Retina Society
Disclosure: Received income in an amount equal to or greater than $250 from: Bayer Health; Quantel Medical.
Rafael Alberto García, MD
Disclosure: Nothing to disclose.
Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society
Disclosure: Nothing to disclose.
R Christopher Walton, MD Professor, Director of Uveitis and Ocular Inflammatory Disease Service, Department of Ophthalmology, University of Tennessee College of Medicine
R Christopher Walton, MD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Retina Society, American College of Healthcare Executives, American Uveitis Society
Disclosure: Nothing to disclose.
Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.
John D Sheppard, Jr, MD, MMSc Professor of Ophthalmology, Microbiology and Molecular Biology, Clinical Director, Thomas R Lee Center for Ocular Pharmacology, Ophthalmology Residency Research Program Director, Eastern Virginia Medical School; President, Virginia Eye Consultants
John D Sheppard, Jr, MD, MMSc is a member of the following medical societies: American Academy of Ophthalmology, American Society for Microbiology, American Society of Cataract and Refractive Surgery, American Uveitis Society, Association for Research in Vision and Ophthalmology
Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: 1-800-DOCTORS; AbbVie; Alcon; Aldeyra; Allergan; Alphaeon; ArcScan; Baush+Lomb; Bio-Tissue; Clearside; EyeGate; Hovione; Mededicus; NovaBay; Omeros; Pentavision; Portage; Santen; Science Based Health; Senju; Shire; Sun Pharma; TearLab;TearScience;Topivert<br/>Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Alcon; Allergan; Bausch+Lomb; Bio-tissue; EyeGate;Hovione;LayerBio; NovaBay;Omeros;Portage; Santen; Shire; Stemnion; Sun Pharma;TearLab;TearScience; Topivert <br/>Received research grant from: Alcon; Aldeyra; allergan; Baush+ Lomb; EyeGate; Hovione; Kala; Ocular Therapeutix;Pfizer; RPS; Santen;Senju;Shire;Topcon; Xoma.
Teodoro Evans, MD Consulting Surgeon, Vitreo-Retinal Section, Clinica de Ojos, Costa Rica
Disclosure: Nothing to disclose.
Ocular Toxoplasmosis
Research & References of Ocular Toxoplasmosis|A&C Accounting And Tax Services
Source
0 Comments